英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
proudness查看　proudness　在百度字典中的解释百度英翻中〔查看〕
proudness查看　proudness　在Google字典中的解释Google英翻中〔查看〕
proudness查看　proudness　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • TEVIMBRA - accessdata. fda. gov
    1 INDICATIONS AND USAGE 1 1 Esophageal Cancer First-Line Treatment of Esophageal Squamous Cell Carcinoma TEVIMBRA, in combination with platinum-containing chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1)
  • Frontiers | Tislelizumab efficacy and safety compared to . . .
    Tislelizumab efficacy and safety compared to other anti–PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma
  • Oncology Drug Reference Sheet: Tislelizumab-Jsgr - ons. org
    Tislelizumab-jsgr (Tevimbra®) is a programmed cell death protein-1 (PD-1) blocking antibody approved in the United States in 2024 for the treatment of certain esophageal and gastric cancers It is administered via IV and works by enhancing the immune system’s ability to target cancer cells
  • Tislelizumab: Side Effects, Uses, Dosage, Interactions, Warnings
    Tislelizumab is a prescription medication indicated for unresectable or metastatic esophageal squamous cell carcinoma (ESCC) in patients previously treated with systemic chemotherapy that did not include a PD-(L) 1 inhibitor
  • First-Line Tislelizumab Plus Chemotherapy Approved in ESCC . . .
    The FDA today approved tislelizumab (Tevimbra; BeiGene) plus chemotherapy for the first-line treatment of patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose
  • TEVIMBRA® (tislelizumab-jsgr) for Esophageal Squamous Cell . . .
    The efficacy of tislelizumab-jsgr as first-line treatment in patients with ESCC was evaluated in RATIONALE-306 (NCT03783442), a global, randomized, placebo-controlled, double-blind study in patients with unresectable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC)
  • First-Line Tislelizumab Plus Chemotherapy for Esophageal . . .
    Introduction The United States Food and Drug Administration Oncologic Drugs Advisory Committee voted (September 2024) against the use of programmed cell death protein-1 inhibitors for first-line treatment of advanced or metastatic unresectable esophageal squamous cell carcinoma (ESCC) with a programmed death-ligand 1 (PD-L1) expression Tumor Area Positivity (TAP) score < 1% or combined
  • Tevimbra: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Tevimbra is used to treat adults with certain types of esophageal squamous cell carcinoma (ESCC), gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma that has spread (metastasized) or cannot be surgically removed
  • Tislelizumab Dosage Guide + Max Dose, Adjustments - Drugs. com
    Detailed Tislelizumab dosage information for adults Includes dosages for Esophageal Carcinoma and Gastric Cancer; plus renal, liver and dialysis adjustments
  • Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT . . .
    Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT as first-line treatment for locally advanced (LA), unresectable esophageal squamous cell carcinoma (ESCC): PD-L1 tumor area positivity (TAP) score ≥1% subgroup analysis of RATIONALE-306





中文字典-英文字典  2005-2009